Efficacy of rituximab on the various predominant organ involvements
| Before rituximab | After rituximab | ||
|---|---|---|---|
| Systemic organ involvement | 74 | Systemic efficacy | 44 (59%) |
| Articular | 27 | 17 (63%) | |
| Nervous system | 18 | 8 (44%) | |
| CNS | 6 | 2 (33%) | |
| Multiple sclerosis-like manifestations | 4 | 0 | |
| Transverse myelitis | 1 | 1 | |
| Anxiety/depression | 1 | 1 | |
| PNS | 12 | 6 (50%) | |
| Mixed sensorimotor polyneuropathy | 6 | 3 | |
| Sensory painful neuropathy (including sensory ataxic neuropathy) | 4 | 2 | |
| Mononeuritis multiplex | 2 | 1 | |
| Pulmonary | 9 | 7 (78%) | |
| Vasculitis | 8 | 5 (62.5%) | |
| Renal | 6 | 5 (83.3%) | |
| Muscular | 3 | 0 (0%) | |
| Haematological | 2 | 2 (100%) | |
| Autoimmune pancreatitis | 1 | 1 (100%) | |
| Glandular involvement | 4 | Glandular efficacy | 2 (50%) |
| Hypertrophy of lachrymal glands | 1 | 0 | |
| Sclera vasculitis | 1 | 0 | |
| parotid hypertrophy | 2 | 2 | |
| ESSDAI before rituximab (n=72) | 11.0 (2–31) | ESSDAI after rituximab (n=72) | 7.5 (0–26) |
| Corticosteroids (mg/day) (n=29) | 17.6 | Corticosteroids after rituximab (n=23) | 10.8 |
Results are expressed as n (%).
CNS, central nervous system; ESSDAI, European Sjögren's syndrome disease activity index; PNS, peripheral nervous system.